ES2464731T3 - Compuestos y procedimientos para reducir el reclutamiento y/o migración de células polimorfonucleares - Google Patents

Compuestos y procedimientos para reducir el reclutamiento y/o migración de células polimorfonucleares Download PDF

Info

Publication number
ES2464731T3
ES2464731T3 ES09825058.2T ES09825058T ES2464731T3 ES 2464731 T3 ES2464731 T3 ES 2464731T3 ES 09825058 T ES09825058 T ES 09825058T ES 2464731 T3 ES2464731 T3 ES 2464731T3
Authority
ES
Spain
Prior art keywords
oligonucleotide
cells
idx9059
pmn
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09825058.2T
Other languages
English (en)
Spanish (es)
Inventor
Charlotte Admyre
Lars-Göran AXELSSON
Oliver Von Stein
Arezou Zargari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Index Pharmaceuticals AB
Original Assignee
Index Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals AB filed Critical Index Pharmaceuticals AB
Application granted granted Critical
Publication of ES2464731T3 publication Critical patent/ES2464731T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ES09825058.2T 2008-11-04 2009-10-28 Compuestos y procedimientos para reducir el reclutamiento y/o migración de células polimorfonucleares Active ES2464731T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11128408P 2008-11-04 2008-11-04
SE0802338 2008-11-04
SE0802338 2008-11-04
US111284P 2008-11-04
PCT/SE2009/051227 WO2010053430A1 (en) 2008-11-04 2009-10-28 Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells

Publications (1)

Publication Number Publication Date
ES2464731T3 true ES2464731T3 (es) 2014-06-03

Family

ID=42153087

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09825058.2T Active ES2464731T3 (es) 2008-11-04 2009-10-28 Compuestos y procedimientos para reducir el reclutamiento y/o migración de células polimorfonucleares
ES14154643.2T Active ES2641751T3 (es) 2008-11-04 2009-10-28 Compuestos y métodos para reducir el reclutamiento y/o la migración de células polimorfonucleares

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14154643.2T Active ES2641751T3 (es) 2008-11-04 2009-10-28 Compuestos y métodos para reducir el reclutamiento y/o la migración de células polimorfonucleares

Country Status (11)

Country Link
US (2) US8877724B2 (enExample)
EP (2) EP2806028B1 (enExample)
JP (1) JP5749651B2 (enExample)
AU (1) AU2009311748B2 (enExample)
CA (1) CA2778938C (enExample)
DK (2) DK2806028T3 (enExample)
ES (2) ES2464731T3 (enExample)
HR (1) HRP20171360T1 (enExample)
LT (1) LT2806028T (enExample)
PL (1) PL2806028T3 (enExample)
WO (1) WO2010053430A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2560782T3 (es) * 2008-11-04 2016-02-22 Index Pharmaceuticals Ab Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC
EP2468866A1 (en) 2010-12-21 2012-06-27 Index Pharmaceuticals AB Biologically active oligonucleotides capable of modulating the immune system
CA2859698C (en) 2010-12-21 2021-03-02 Index Pharmaceuticals Ab Methods for identifying biologically active oligonucleotides capable of modulating the immune system
EP2468867A1 (en) 2010-12-21 2012-06-27 Index Pharmaceuticals AB Methods for identifying biologically active oligonucleotides capable of modulating the immune system
WO2012084991A1 (en) 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
US9873878B2 (en) * 2015-03-30 2018-01-23 University Of Louisville Research Foundation, Inc. Compositions and methods for use in treating silicosis and lung cancer
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
JP2021131228A (ja) * 2018-04-27 2021-09-09 国立大学法人 東京大学 難治性喘息の予防又は治療剤をスクリーニングする方法、及び難治性喘息の予防又は治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
SE9602300D0 (sv) * 1996-06-11 1996-06-11 Karolinska Innovations Ab New composition and methods
ES2246230T3 (es) 1999-03-18 2006-02-16 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina y su utilizacion.
US6489311B1 (en) * 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
JP2006527741A (ja) * 2003-06-19 2006-12-07 シーティーティー キャンサー ターゲッティング テクノロジーズ オイ 細胞遊走の阻害剤
SE0400399D0 (sv) 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
WO2007030580A2 (en) * 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
WO2007030581A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
US8309529B2 (en) 2007-05-04 2012-11-13 Index Pharmaceuticals Ab Tumour growth inhibitory compounds and methods of their use
ES2560782T3 (es) 2008-11-04 2016-02-22 Index Pharmaceuticals Ab Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC
US20110280934A1 (en) 2008-11-04 2011-11-17 Asa Karlsson Increased Expression of Specific Antigens

Also Published As

Publication number Publication date
WO2010053430A1 (en) 2010-05-14
AU2009311748A1 (en) 2010-05-14
EP2342341A1 (en) 2011-07-13
AU2009311748B2 (en) 2014-08-21
EP2342341A4 (en) 2013-01-09
US10046006B2 (en) 2018-08-14
JP5749651B2 (ja) 2015-07-15
US20110301225A1 (en) 2011-12-08
US20150099799A1 (en) 2015-04-09
CA2778938C (en) 2019-07-02
EP2806028A2 (en) 2014-11-26
DK2342341T3 (da) 2014-05-12
LT2806028T (lt) 2017-12-11
US8877724B2 (en) 2014-11-04
EP2806028A3 (en) 2015-03-11
EP2342341B1 (en) 2014-03-05
HRP20171360T1 (hr) 2017-11-03
DK2806028T3 (en) 2017-10-09
PL2806028T3 (pl) 2017-11-30
JP2012507307A (ja) 2012-03-29
EP2806028B1 (en) 2017-07-12
ES2641751T3 (es) 2017-11-13
CA2778938A1 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
US10046006B2 (en) Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells
Guan et al. Dysregulated chemokine signaling in cystic fibrosis lung disease: a potential therapeutic target
JP5914567B2 (ja) 浮腫を治療または軽減するための新規な化合物およびその使用方法
CN109937053B (zh) 用于治疗黄斑变性的含有mTOR抑制剂的药物组合物
US9260719B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
ES2956776T3 (es) Composición farmacéutica que comprende miARN-3140 para su uso en el tratamiento del cáncer
US9610331B2 (en) Methods for hematopoietic precursor mobilization
ES2560782T3 (es) Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC
CN104083761A (zh) microRNA-101抑制剂在制备预防或治疗骨关节炎药物中的应用
EP3352777B1 (en) Engrailed for use in the treatment of dna-damage in a patient suffering from parkinson disease
JP6564952B2 (ja) 腫瘍を予防・治療する医薬およびその用途
CN115317625B (zh) 一种小干扰rna在制备改善鼻咽癌预后的药物中的应用
ES2920052T3 (es) Formulaciones de alicaforsen
CA2999209C (en) Homeoproteins for use in the treatment of neurodegenerative disorders
CN107951918A (zh) 金银花石油醚部位提取物在制备治疗肺纤维化药物中的应用
Xin et al. Aberrant Neuronal Excitation in Acute Ischemic Stroke Exacerbates the Neuronal Injury by Activating Local Microglia and Neuron Through Unique Small Extracellular Vesicles
CN113930423A (zh) 保护心肌细胞免受应激损伤的saRNA及其应用
CN118903376A (zh) 一种重组DcR3-SUMO蛋白在治疗脓毒症药物中的应用